At the news
? BULLISHIMPACT 7/10 8-K filed Jun 1, 2026 at 16:01 ET
Spyre Therapeutics expanded its license agreement with Paragon Therapeutics, removing the previous restriction that limited SPY003 (an IL-23p19 antibody) to inflammatory bowel disease. The new 'Field' covers all therapeutic areas, subject to dosing restrictions: no combination-trial dosing outside IBD before June 2028 and no monotherapy dosing outside IBD before June 2030. This materially increases the total addressable market for Spyre's lead asset, though the near-term clinical focus remains IBD.
- License field expanded from inflammatory bowel disease to all therapeutic areas (prophylaxis, palliation, treatment, diagnosis of all human diseases).
- Monotherapy dosing outside IBD restricted until June 1, 2030; combination dosing outside IBD restricted until June 1, 2028.
- If Spyre or the retained IL-23 project licensee consummates a material transaction (change of control or sale of lead IL-23p19 asset post-Phase II), the monotherapy restriction outside IBD terminates early on June 1, 2028.
- Amendment effective May 29, 2026; filed June 1, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access